Earnings expected on 2026-04-16. High gap risk. Recommendation: DO NOT OPEN NEW POSITIONS.
ABT
AI Execution Plan
ABT Q4 2025 revenue miss at $11.46B vs $11.80B est., softer Q1 2026 guidance caused 14% stock drop in Jan 2026. Analysts see buy opportunity as 'Dividend King' with 10%+ earnings growth projected. Headlines: '3 Reasons to Buy After Sell-Off' (Motley Fool), CEO insider buy $2M shares.
RSI(14): ~20 (deeply oversold). Stochastic %K: 8 (oversold). MACD(12,26): -3.09 (sell). All MAs (5-200 day): Strong sell. Oversold indicators suggest potential rebound amid downtrend.
3-Month AI Outlook
Bullish recovery expected. Analysts forecast 2026 EPS $5.67 (+10%), revenue $47.9B. Oversold technicals and growth in diagnostics/devices support rebound to $120+.
Option Chain
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
| Strike | Bid | Ask | IV % | Vol | OI | Time |
|---|
Earnings History: ABT
Abbott Reports Strong Third-Quarter 2025 Earnings with Continued Growth**
Oct 15, 2025****Summary:** In the third quarter of 2025, Abbott reported revenue of $11.369 billion, reflecting a growth of 6.9 percent compared to the same quarter last year. The company achieved a net income of $1.644 billion, with a GAAP diluted earnings per share (EPS) of $0.94 and an adjusted diluted EPS of $1.30. Additionally, Abbott reaffirmed its full-year 2025 organic sales growth guidance, expecting a range of 7.5% to 8.0% excluding COVID-19 related sales. The company's adjusted diluted EPS guidance has been narrowed to between $5.12 and $5.18, indicating double-digit growth at the midpoint. Research and development (R&D) expenses for the quarter increased by 7.5 percent to $766 million, supporting ongoing product innovation and development. Abbott also highlighted significant regulatory approvals, including the TriClip® treatment in Japan and an expanded indication for its Navitor® TAVI system in Europe. Lastly, Abbott declared its 407th consecutive quarterly dividend of $0.59 per share, payable on November 17, 2025, reinforcing its commitment to returning value to shareholders as it has increased dividends for 53 consecutive years.
Abbott Reports Strong Second-Quarter 2025 Financial Results
Jul 17, 2025In the second quarter of 2025, Abbott reported sales of $11.142 billion, reflecting a growth of 7.4% compared to the previous year. The company achieved a net income of $1.779 billion, resulting in a GAAP diluted earnings per share (EPS) of $1.01 and an adjusted diluted EPS of $1.26, which marks a significant increase from the prior year. Additionally, Abbott's gross margin improved to 52.7% of sales, with an adjusted gross margin reaching 57.0%, showing a 100 basis point increase. The operating margin was reported at 18.4%, while the adjusted operating margin also increased by 100 basis points to 22.9% of sales. The company completed enrollment ahead of schedule in its FlexPulse U.S. trial for the TactiFlex™ Duo Pulsed Field Ablation System, aimed at treating heart rhythm disorders. Abbott also received FDA approval for its innovative Tendyne™ transcatheter mitral valve replacement system, expanding its product offerings in cardiovascular care. Looking ahead, Abbott projects full-year 2025 organic sales growth of 7.5% to 8.0%, excluding COVID-19 testing-related sales. The company anticipates an adjusted diluted EPS of $5.10 to $5.20 for the year, demonstrating strong financial momentum into 2026.
Ex-Dividend Date
Apr 14, 2026MEDIUM
Strategy Overview
Jason Wheel is a systematic, AI‑enhanced trading framework built on probability theory and volatility‑based edge extraction. Designed for the US options market, the system focuses on constructing high‑probability Credit Spread strategies that capture Theta decay while maintaining strict quantitative risk controls to mitigate tail events and support long‑term, stable capital growth.
Rather than relying on directional speculation, the system operates as a closed‑loop asset engine integrating: Macro Risk Control, Multi-dimensional Quantitative Screening, AI-Assisted Decision Making, and Dynamic Position Management.
This architecture enables consistent, rules‑driven execution with an emphasis on risk‑adjusted returns.
Connect with Jason
- Substack: jasonwheel.substack.com
- Email: [email protected]